Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Optellum is an Oxford company founded in 2016 that helps clinicians decide how to manage lung nodules found on scans. Its Virtual Nodule Clinic scores the likelihood of malignancy so patients are neither over-investigated nor diagnosed too late. The software is cleared in the United States and used in lung cancer pathways.
News
SimonMed Launches World's First Seamlessly Integrated AI Lung Nodule Risk Assessment Workflow
SCOTTSDALE, AZ - August 24th, 2026 - SimonMed, one of the largest outpatient medical imaging providers and radiology practices in the United States, today announced a partnership with Optellum, an AI-powered lung cancer diagnostics company, to integrate a
Read more
Report
Coreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathway
OXFORD, England and SEOUL, South Korea, Aug. 13, 2026 - Optellum and Coreline Soft today announced their intent to collaborate across geographies and multiple disease areas to advance AI-enabled lung cancer care across the lung nodule pathway. Under the p
Read more
Report
Optellum Awarded NIHR Funding for Multi-Site NHS Pilot Study for Accelerated Lung Cancer Diagnosis
OXFORD, United Kingdom and HOUSTON, June 15, 2026 - Optellum, a leader in AI-enabled lung cancer diagnostics, today announced it has been awarded funding for a competitive programme, Invention for Innovation (i4i), focused on transformative and disruptive
Read more
Report
Tanner Health and Healthliant Ventures Partner with Optellum to Bring AI for Lung Health to the Region
Carrollton, Georgia, June 10, 2026 - Tanner Health and Healthliant Ventures announce the launch of Optellum's Virtual Nodule Clinic (VNC), an artificial intelligence (AI) platform designed to assist care teams in identifying, risk assessing and managing p
Read more
Report
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
OXFORD, United Kingdom and HOUSTON, United States, June 4, 2026 - Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores
Read more
Report
Pro access
Upgrade to see all 17 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.